Mounjaro patent expiration?

When does the Mounjaro patent expire?

According to data from DrugPatentWatch.com [1], the patent for Mounjaro (tirzepatide) is expected to expire in 2035, with a patent expiration date of August 2035. However, it's essential to note that patent expiration dates can be complex and may involve varying patent terms and regulatory extensions.

What happens if the patent expires early?

If the patent for Mounjaro expires early due to regulatory hurdles or litigation, it could allow generic or biosimilar versions of the drug to enter the market sooner. This could lead to increased competition and potentially lower prices for patients. On the other hand, if the patent remains in force, Eli Lilly and Company, the developer of Mounjaro, may continue to maintain market exclusivity.

Can biosimilars enter the market before patent expiry?

Biosimilars, which are biologically similar versions of an existing drug, can sometimes enter the market before the original patent expires. However, approval for a biosimilar typically requires demonstrating similarity in safety, efficacy, and quality to the original drug, which can be a time-consuming and costly process.

Who would benefit from cheaper Mounjaro alternatives?

Patients and healthcare systems worldwide may benefit from cheaper Mounjaro alternatives, especially those unable to afford the high costs associated with this treatment. Additionally, biosimilars or generic versions of Mounjaro could help reduce healthcare spending and alleviate the burden on public healthcare budgets.

Regulatory challenges and implications

Approval of generic or biosimilar versions of Mounjaro will depend on various regulatory factors, including patent status, clinical data, and manufacturing requirements. Regulatory agencies, such as the FDA, will need to assess the safety and efficacy of these alternatives before granting approval.

Sources:

[1] DrugPatentWatch.com - Tirzepatide Patent Expiration Date